|
| To investigate the mechanism of Hydroxysafflor yellow A in the treatment of hyperlipidemia in LDLR-/- mice based on lipid metabolomics |
| Hits 662 Download times 420 Received:September 30, 2023 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1673-9043.2024.01.01 |
| Key Words
Hydroxysafflor yellow A;hyperlipidemia;lipidomics;metabolism of lipid |
| Author Name | Affiliation | E-mail | | TANG Huajing | Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | LUO Yage | Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | YANG Lei | Youcare Pharmaceutical Group Co., Ltd., Beijing 100176, China | | | XU Baoxin | Youcare Pharmaceutical Group Co., Ltd., Beijing 100176, China | | | XU Jingya | Youcare Pharmaceutical Group Co., Ltd., Beijing 100176, China | | | MIAO Lin | Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | CHAI Lijuan | Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | ZHANG Han | Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | WANG Yi | Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | MAO Haoping | Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | maohaoping@tjutcm.edu.cn |
|
| Abstract
|
| [Objective] To investigate the effect and mechanism of Hydroxysafflor yellow A(HSYA) on lipid metabolism in LDLR-/- mice with hyperlipidemia induced by high-fat diet based on lipid metabolomics. [Methods] Twenty-eight male LDLR-/- mice were divided into control group and high-fat diet group. The control group was fed with normal diet, and the high-fat group was fed with high-fat diet. After 6 weeks, according to the content of LDL-C, the mice were divided into four groups[model group, simvastatin group, low dose HSYA(3.8 mg/kg) and high dose HSYA(7.6 mg/kg)]. The drug was administered for 11 weeks, and high-fat diet was given simultaneously during the drug administration. The content of alanine aminotransferase(ALT), aspartate aminotransferase(AST), triglyceride(TG), total cholesterol(TC), and low-density lipoprotein cholesterol(LDL-C) in serum of mice were detected by automatic biochemical instrument, the pathological morphology of liver histology was observed by hematoxylin-eosin staining, and the fat deposition of liver tissues of mice was observed by oil red O staining, and lipids in the serum of LDLR-/- mice were measured by targeted lipidomic technology. [Results] Compared with the control group, the serum content of LDL-C, TC, TG, AST and ALT in the model group were increased(P<0.05). The liver tissue showed infiltration of lipid droplets of different sizes, disorderly arrangement of hepatocytes, and a large number of lipid deposits. Compared with the model group, the serum content of LDL-C, TC, TG, AST and ALT in the HSYA group were decreased(P<0.05), liver steatosis, lipid deposition and other pathological conditions were improved. The results of lipid profiling showed that there were 14 different lipid molecules(VIP>1, P<0.05). Compared with the model group, 17 lipid molecules in the HSYA group showed the opposite trend and had differences, Respectively PE(18:0/18:1), PE(18:0/18:2), PE(18:0/20:3), PE(18:0/20:4), PE(O-18:0/18:1), PE(O-18:0/20:4), LPE(18:1), LPE(20:4), FFA(22:4), PI(18:0/18:2), PI(16:0/18:1), PI(18:1/18:1), LPI(18:0), PG(18:1/16:1), PG(18:1/18:1), PG(18:1/18:2), PA(18:1/18:1)(VIP>1, P<0.05). [Conclusion] Using lipidomics technology, this study found that HSYA could play a role in the treatment of hyperlipidemia by regulating lipid metabolism in the serum of hyperlipidemia LDLR-/- mice, and provided a new reference for its clinical application. |
|
|
|
|
|
